Physician profile
Michael James Munro
NPI 1871870337
$1,354.82
in general payments reported to CMS, 2019-2025
19 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $81.60 · 2021: $330 · 2022: $153 · 2023: $38.19 · 2024: $246 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.38 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $303.16 | 2019-2025 | Argos, Clareon, Centurion |
| Mallinckrodt Hospital Products INC. | $225.70 | 2021-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $187.59 | 2019-2021 | |
| Biotissue Holdings INC. | $161.16 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $75.39 | 2019-2022 | |
| Allergan, INC. | $58.06 | 2020-2022 | |
| Horizon Therapeutics Plc | $48.34 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $34.01 | 2019-2020 | |
| Amgen INC. | $29.67 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $28.72 | 2019-2020 | |
| Dompe US, INC. | $28.35 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $27.19 | 2024 | Tyrvaya |
| Acacia Pharma INC | $25.01 | 2022 | |
| Glaukos Corporation | $24.88 | 2019 | |
| Apellis Pharmaceuticals, INC. | $23.95 | 2025 | Syfovre |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $21.49 | 2019 | |
| Oasis Medical, INC. | $20.17 | 2019 | |
| Rxsight INC | $19.90 | 2021 | |
| Eyepoint US, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Munro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.